A biomimetic membrane device that modulates the excessive inflammatory response to sepsis

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Ding, Feng ^a   Song, Joon Ho ^b   Jung, Ju Young ^c   Lou, Liandi ^d   Wang, Min ^d   Charles, Linda ^d   Westover, Angela ^d   Smith, Peter L ^d   Pino, Christopher J ^d   Buffington, Deborah A ^d   Humes, H David ^d,e  

^a FUDAN UNIVERSITY   (China)

^b Inha University School of Medicine   (South Korea)

^c Chungnam National University   (South Korea)

^d Innovative BioTherapies Inc   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID CITRATE DEXTROSE; CALCIUM ION; HEPARIN; MYELOPEROXIDASE; POLYSULFONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL MEMBRANE; BIOMIMETICS; CALCIUM BLOOD LEVEL; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ESCHERICHIA COLI INFECTION; EXPERIMENTAL PIG; EXTRACORPOREAL CIRCULATION; HEART STRESS; IMMUNOMODULATION; INFLAMMATION; KIDNEY DYSFUNCTION; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE AGGREGATION; LUNG SEQUESTRATION; NONHUMAN; PROCESS DEVELOPMENT; SEPTIC SHOCK; SURVIVAL TIME; SYSTEMIC CIRCULATION; ANIMAL; IMMUNOHISTOCHEMISTRY; MOLECULAR MIMICRY; SEPSIS; SWINE;

ANIMALIA; ESCHERICHIA COLI; SUIDAE;

ANIMALS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MEMBRANES, ARTIFICIAL; MOLECULAR MIMICRY; SEPSIS; SWINE;

EID: 79954997539     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018584     Document Type: Article

References (36)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310.
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL, (2007) Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35: 1244-1250.
3. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, et al. (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34: 344-353.
4. Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M, et al. (2009) Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 37: 222-232.
5. Hotchkiss RS, Karl IE, (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150.
6. Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, et al. (2006) Neutrophils in development of multiple organ failure in sepsis. Lancet 368: 157-169.
7. Schouten M, Wiersinga WJ, Levi M, van der Poll T, (2008) Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83: 536-545.
8. Marshall JC, (2005) Neutrophils in the pathogenesis of sepsis. Crit Care Med 33: S502-505.
9. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, et al. (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25: 551-573.
10. Boxer LA, (2003) Neutrophil abnormalities. Pediatr Rev 24: 52-62.
11. Aird WC, (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101: 3765-3777.
12. Sutton TA, Fisher CJ, Molitoris BA, (2002) Endothelial injury and dysfunction during the extension phase of acute renal failure. Kidney Int 62: 1539-1549.
13. Sutton TA, Mang HE, Campos SB, Sandoval RM, Yoder MC, et al. (2003) Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol 285: F191-198.
14. Welbourn CR, Young Y, (1992) Endotoxin, septic shock and acute lung injury: neutrophils, macrophages and inflammatory mediators. Br J Surg 79: 998-1003.
15. Andonegui G, Zhou H, Bullard D, Kelly MM, Mullaly SC, et al. (2009) Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal systemic Gram-negative bacterial infection. J Clin Invest 119: 1921-1930.
16. Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, et al. (1998) A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect Dis 178: 1075-1080.
17. Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, et al. (2003) Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 31: 367-373.
18. Kaneider NC, Leger AJ, Kuliopulos A, (2006) Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J 273: 4416-4424.
19. Tintinger G, Steel HC, Anderson R, (2005) Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control. Clin Exp Immunol 141: 191-200.
20. Humes HD, Buffington DA, Lou L, Abrishami S, Wang M, et al. (2003) Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med 31: 2421-2428.
21. Pinnick RV, Wiegmann TB, Diederich DA, (1983) Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 308: 258-261.
22. Lohr JW, Slusher S, Diederich D, (1989) Safety of regional citrate hemodialysis in acute renal failure. Am J Kidney Dis 13: 104-107.
23. Tobe SW, Aujla P, Walele AA, Oliver MJ, Naimark DM, et al. (2003) A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care 18: 121-129.
24. Fietz S, Bondzio A, Moschos A, Hertsch B, Einspanier R, (2008) Measurement of equine myeloperoxidase (MPO) activity in synovial fluid by a modified MPO assay and evaluation of joint diseases- an initial case study. Res Vet Sci 84: 347-353.
25. Abramoff MD, Magelhaes PH, Ram SJ, (2004) Image Processing with ImageJ. Biophotonics International 11: 36-42.
26. Humes HD, Sobota JT, Ding F, Song JH, The RAD Investigator Group (2010) A selective cytopheretic inhibitory device to treat the immunological dysregulation of acute and chronic renal failure. Blood Purication 29: 183-190.
27. Damsgaard CT, Lauritzen L, Calder PC, Kjaer TM, Frokiaer H, (2009) Whole-blood culture is a valid low-cost method to measure monocytic cytokines- a comparison of cytokine production in cultures of human whole-blood, mononuclear cells and monocytes. J Immunol Methods 340: 95-101.
28. Wutzler S, Maier M, Lehnert M, Henrich D, Walcher F, et al. (2009) Suppression and recovery of LPS-stimulated monocyte activity after trauma is correlated with increasing injury severity: a prospective clinical study. J Trauma 66: 1273-1280.
29. Klebanoff SJ, (2005) Myeloperoxidase: friend and foe. J Leukoc Biol 77: 598-625.
30. Fan ST, Edgington TS, (1993) Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J Immunol 150: 2972-2980.
31. Hoesel LM, Neff TA, Neff SB, Younger JG, Olle EW, et al. (2005) Harmful and protective roles of neutrophils in sepsis. Shock 24: 40-47.
32. Navarini AA, Lang KS, Verschoor A, Recher M, Zinkernagel AS, et al. (2009) Innate immune-induced depletion of bone marrow neutrophils aggravates systemic bacterial infections. Proc Natl Acad Sci U S A 106: 7107-7112.
33. Mandeville JT, Maxfield FR, (1996) Calcium and signal transduction in granulocytes. Curr Opin Hematol 3: 63-70.
34. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, et al. (2004) Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 65: 1357-1365.
35. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, et al. (2006) Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 113: 1871-1878.
36. Ding F, Yevzlin AS, Xu ZY, Zhou U, Xie QH, et al. (2010) The Effects of a Novel Therapeutic Device on Acute Kidney Injury Outcomes in the Intensive Care Unit: A Pilot Study. ASAIO In Press.